Management of ABPA
For acute ABPA (newly diagnosed or exacerbation), treat with either oral prednisolone monotherapy (0.5 mg/kg/day for 2-4 weeks, tapered over 4 months) OR oral itraconazole monotherapy (for 4 months), with combination therapy reserved only for recurrent exacerbations. 1
Treatment Decision Algorithm
Step 1: Determine if Treatment is Needed
Asymptomatic ABPA patients do not routinely require systemic therapy 1. However, treatment should be individualized in these specific scenarios:
- Patients with well-controlled asthma on high-dose inhaled steroids who have bronchiectasis or mucus plugging on CT
- Patients with prolonged mucus plugging (risk of progression to irreversible bronchiectasis)
If not treating asymptomatic patients, monitor with:
- Clinical review every 3-6 months
- Chest radiograph every 3-6 months
- Serum total IgE every 3-6 months 1
Step 2: Choose Initial Therapy for Acute ABPA
Two equally acceptable first-line monotherapy options:
Option A: Oral Prednisolone (Most Rapid Acting)
- Dose: 0.5 mg/kg/day for 2-4 weeks, then taper and complete over 4 months total 1
- Advantages: Most rapid symptom relief 1
- Disadvantages: More adverse events than antifungals
- Critical warning: Avoid methylprednisolone when combined with itraconazole (high risk of Cushing's syndrome and adrenal insufficiency) 1
- Additional warning: Inhaled budesonide or fluticasone combined with itraconazole can also cause Cushing's syndrome 1
Option B: Oral Itraconazole
- Duration: 4 months 1
- Advantages: Similar efficacy to glucocorticoids with better safety profile and slower trajectory to improvement 1
- Evidence level: Level II (single RCT) 1
Alternative azoles if itraconazole not tolerated:
- Voriconazole (similar efficacy, Level II evidence) 1
- Posaconazole (third-line for intolerance/failure, Level III evidence) 1
Step 3: Managing Treatment-Dependent or Recurrent ABPA
For recurrent ABPA exacerbations: Use combination prednisolone + itraconazole 1
For steroid-dependent ABPA, add:
- Itraconazole (steroid-sparing effect, Level II evidence) 1
- OR Omalizumab (reduces exacerbations, steroid-sparing, Level II evidence) 1
- OR Other biologics (mepolizumab, benralizumab, dupilumab, tezepelumab - Level III evidence) 1
Recent real-world data from 2026 shows that combination therapy with corticosteroids + antifungal + biologic agents produces the most comprehensive clinical and immunologic responses, with significant improvements in FEV1, ACT scores, and reductions in total IgE and eosinophil counts 2.
Step 4: Maintenance Therapy Considerations
Nebulized amphotericin B may reduce ABPA exacerbations and increase time-to-first exacerbation when used as maintenance therapy in stable ABPA (Level II evidence) 1
Key Treatment Principles
The treatment goals are:
- Symptom relief
- Improving asthma control
- Preventing asthma and ABPA exacerbations
- Preventing bronchiectasis progression
- Minimizing therapy-related adverse events 1
Critical Pitfalls to Avoid
High-dose inhaled steroids alone do NOT work as primary therapy for acute ABPA (Level II evidence) 1 - they are insufficient for symptom control or reducing exacerbations
Drug interactions: The combination of itraconazole with methylprednisolone or high-dose inhaled corticosteroids (budesonide/fluticasone) significantly increases risk of Cushing's syndrome 1
Don't use combination therapy upfront: Reserve prednisolone + itraconazole combination only for recurrent exacerbations, not initial treatment 1
Monitor for treatment response using objective multidimensional criteria including clinical symptoms, pulmonary function, imaging, and immunological markers 1
Special Considerations for ABPM
For allergic bronchopulmonary mycosis (caused by fungi other than Aspergillus), treatment principles are similar to ABPA, but the choice of antifungal should be guided by the specific implicated fungus 1